143 related articles for article (PubMed ID: 38574101)
21. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver.
Wang ZH; Zheng KI; Wang XD; Qiao J; Li YY; Zhang L; Zheng MH; Wu J
Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):452-459. PubMed ID: 34256994
[TBL] [Abstract][Full Text] [Related]
22. Longitudinal 16S rRNA Sequencing Reveals Relationships among Alterations of Gut Microbiota and Nonalcoholic Fatty Liver Disease Progression in Mice.
Zhuge A; Li S; Lou P; Wu W; Wang K; Yuan Y; Xia J; Li B; Li L
Microbiol Spectr; 2022 Jun; 10(3):e0004722. PubMed ID: 35647690
[TBL] [Abstract][Full Text] [Related]
23. Fibrinogen-like protein 2 aggravates nonalcoholic steatohepatitis via interaction with TLR4, eliciting inflammation in macrophages and inducing hepatic lipid metabolism disorder.
Hu J; Wang H; Li X; Liu Y; Mi Y; Kong H; Xi D; Yan W; Luo X; Ning Q; Wang X
Theranostics; 2020; 10(21):9702-9720. PubMed ID: 32863955
[No Abstract] [Full Text] [Related]
24. Circulating microRNA expression and nonalcoholic fatty liver disease in adolescents with severe obesity.
Li YJ; Baumert BO; Stratakis N; Goodrich JA; Wu HT; He JX; Zhao YQ; Aung MT; Wang HX; Eckel SP; Walker DI; Valvi D; La Merrill MA; Ryder JR; Inge TH; Jenkins T; Sisley S; Kohli R; Xanthakos SA; Baccarelli AA; McConnell R; Conti DV; Chatzi L
World J Gastroenterol; 2024 Jan; 30(4):332-345. PubMed ID: 38313232
[TBL] [Abstract][Full Text] [Related]
25. FoxO3 Modulates LPS-Activated Hepatic Inflammation in Turbot (
Pan M; Liu J; Huang D; Guo Y; Luo K; Yang M; Gao W; Xu Q; Zhang W; Mai K
Front Immunol; 2021; 12():679704. PubMed ID: 34276667
[TBL] [Abstract][Full Text] [Related]
26. Potential biomarkers in NASH-induced liver cirrhosis with hepatocellular carcinoma: A preliminary work on roles of exosomal miR-182, miR-301a, and miR-373.
Muhammad Yusuf AN; Raja Ali RA; Muhammad Nawawi KN; Mokhtar NM
Malays J Pathol; 2020 Dec; 42(3):377-384. PubMed ID: 33361718
[TBL] [Abstract][Full Text] [Related]
27. Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes.
Bayliss J; Ooi GJ; De Nardo W; Shah YJH; Montgomery MK; McLean C; Kemp W; Roberts SK; Brown WA; Burton PR; Watt MJ
Front Endocrinol (Lausanne); 2021; 12():642432. PubMed ID: 33746906
[TBL] [Abstract][Full Text] [Related]
28. Integrative metabolomics highlights gut microbiota metabolites as novel NAFLD-related candidate biomarkers in children.
Luo J; Luo M; Kaminga AC; Wei J; Dai W; Peng Y; Zhao K; Duan Y; Xiao X; Ouyang S; Yao Z; Liu Y; Pan X
Microbiol Spectr; 2024 Apr; 12(4):e0523022. PubMed ID: 38445874
[TBL] [Abstract][Full Text] [Related]
29. From gut to liver: unveiling the differences of intestinal microbiota in NAFL and NASH patients.
Huang F; Lyu B; Xie F; Li F; Xing Y; Han Z; Lai J; Ma J; Zou Y; Zeng H; Xu Z; Gao P; Luo Y; Bolund L; Tong G; Fengping X
Front Microbiol; 2024; 15():1366744. PubMed ID: 38638907
[TBL] [Abstract][Full Text] [Related]
30. The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis.
Sharma M; Mitnala S; Vishnubhotla RK; Mukherjee R; Reddy DN; Rao PN
J Clin Exp Hepatol; 2015 Jun; 5(2):147-58. PubMed ID: 26155043
[TBL] [Abstract][Full Text] [Related]
31. Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis.
Becker PP; Rau M; Schmitt J; Malsch C; Hammer C; Bantel H; Müllhaupt B; Geier A
PLoS One; 2015; 10(11):e0142661. PubMed ID: 26565986
[TBL] [Abstract][Full Text] [Related]
32. CD44 is a key player in non-alcoholic steatohepatitis.
Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
[TBL] [Abstract][Full Text] [Related]
33. Association of serum ferritin with non-alcoholic fatty liver disease: a meta-analysis.
Du SX; Lu LL; Geng N; Victor DW; Chen LZ; Wang C; Yue HY; Xin YN; Xuan SY; Jin WW
Lipids Health Dis; 2017 Dec; 16(1):228. PubMed ID: 29197393
[TBL] [Abstract][Full Text] [Related]
34. Noninvasive diagnostic criteria for nonalcoholic steatohepatitis based on gene expression levels in peripheral blood mononuclear cells.
Kado A; Tsutsumi T; Enooku K; Fujinaga H; Ikeuchi K; Okushin K; Moriya K; Yotsuyanagi H; Koike K
J Gastroenterol; 2019 Aug; 54(8):730-741. PubMed ID: 30830270
[TBL] [Abstract][Full Text] [Related]
35. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach.
Del Chierico F; Nobili V; Vernocchi P; Russo A; De Stefanis C; Gnani D; Furlanello C; Zandonà A; Paci P; Capuani G; Dallapiccola B; Miccheli A; Alisi A; Putignani L
Hepatology; 2017 Feb; 65(2):451-464. PubMed ID: 27028797
[TBL] [Abstract][Full Text] [Related]
36. Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts.
Mayo R; Crespo J; Martínez-Arranz I; Banales JM; Arias M; Mincholé I; Aller de la Fuente R; Jimenez-Agüero R; Alonso C; de Luis DA; Vitek L; Stritesky J; Caballería J; Romero-Gómez M; Martín-Duce A; Mugüerza Huguet JM; Busteros-Moraza JI; Idowu MO; Castro A; Martínez-Chantar ML; Ortiz P; Bruha R; Lu SC; Bedossa P; Noureddin M; Sanyal AJ; Mato JM
Hepatol Commun; 2018 Jul; 2(7):807-820. PubMed ID: 30027139
[TBL] [Abstract][Full Text] [Related]
37. MiR-182-5p Is Upregulated in Hepatic Tissues from a Diet-Induced NAFLD/NASH/HCC C57BL/6J Mouse Model and Modulates Cyld and Foxo1 Expression.
Compagnoni C; Capelli R; Zelli V; Corrente A; Vecchiotti D; Flati I; Di Vito Nolfi M; Angelucci A; Alesse E; Zazzeroni F; Tessitore A
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298191
[TBL] [Abstract][Full Text] [Related]
38. Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies.
Reddy YK; Marella HK; Jiang Y; Ganguli S; Snell P; Podila PSB; Maliakkal B; Satapathy SK
J Clin Exp Hepatol; 2020; 10(3):245-254. PubMed ID: 32405181
[TBL] [Abstract][Full Text] [Related]
39. The effects of S-nitrosylation-induced PPARγ/SFRP5 pathway inhibition on the conversion of non-alcoholic fatty liver to non-alcoholic steatohepatitis.
Wang H; Li F; Feng J; Wang J; Liu X
Ann Transl Med; 2021 Apr; 9(8):684. PubMed ID: 33987382
[TBL] [Abstract][Full Text] [Related]
40. A metabolomics approach to the validation of predictive metabolites and phenotypic expression in non-alcoholic fatty liver disease.
Ganesan R; Gupta H; Jeong JJ; Sharma SP; Won SM; Oh KK; Yoon SJ; Kim DJ; Suk KT
Life Sci; 2023 Jun; 322():121626. PubMed ID: 37003543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
